Company: BLCO
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001860742-25-000023
Chunk: 78

Company: Bausch & Lomb Corp
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 8
Chunk 78
---
 increases in revenue were partially offset by: (i) decreased net realized pricing of $47 million, driven by our Pharmaceuticals segment and (ii) the impact of divestitures and discontinuations of $7 million, primarily relating to the discontinuation of certain products within our Vision Care segment.The following table presents segment revenues, segment revenues as a percentage of total revenues and the period-over-period changes in segment revenues for the nine months ended September 30, 2025 and 2024. 20252024Change(in millions)AmountPct.AmountPct.AmountPct.Segment RevenuesVision Care$2,145 58 %$2,016 57 %$129 6 %Pharmaceuticals906 25 %883 25 %23 3 %Surgical645 17 %612 18 %33 5 %Total revenues$3,696 100 %$3,511 100 %$185 5 %Constant Currency Revenues and Constant Currency Revenue Growth (non-GAAP)The following table presents a reconciliation of Revenues to constant currency revenues (non-GAAP) and the period-over-period changes in constant currency revenue (non-GAAP) for the nine months ended September 30, 2025 and 2024. Constant Currency Revenues (non-GAAP) and Constant Currency Revenue Growth (non-GAAP) are defined in the previous section titled “Constant Currency Revenues and Constant Currency Revenue Growth (non-GAAP)”. Nine Months Ended September 30, 2025Nine Months Ended September 30, 2024Change inConstant Currency Revenue (Non-GAAP)RevenueasReportedChanges in Exchange RatesConstant Currency Revenue (Non-GAAP)RevenueasReported(in millions)AmountPct.Vision Care$2,145 $(12)$2,133 $2,016 $117 6 %Pharmaceuticals906 (2)904 883 21 2 %Surgical645 (7)638 612 26 4 %Total$3,696 $(21)$3,675 $3,511 $164 5 %Vision Care Segment RevenueThe Vision Care segment revenue was $2,145 million and $2,016 million for the nine months ended September 30, 2025 and 2024, respectively, an increase of $129 million, or 6%. The increase was primarily driven by sales from our dry eye portfolio